1. Home
  2. AURA vs VNDA Comparison

AURA vs VNDA Comparison

Compare AURA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aura Biosciences Inc.

AURA

Aura Biosciences Inc.

HOLD

Current Price

$5.28

Market Cap

396.8M

Sector

Health Care

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$8.19

Market Cap

425.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AURA
VNDA
Founded
2007
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.8M
425.5M
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
AURA
VNDA
Price
$5.28
$8.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$20.20
$13.13
AVG Volume (30 Days)
178.6K
2.8M
Earning Date
11-13-2025
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$212,074,000.00
Revenue This Year
N/A
$12.01
Revenue Next Year
N/A
$21.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.12
52 Week Low
$4.35
$3.81
52 Week High
$8.60
$9.60

Technical Indicators

Market Signals
Indicator
AURA
VNDA
Relative Strength Index (RSI) 32.59 68.93
Support Level $5.30 $6.87
Resistance Level $6.34 $9.60
Average True Range (ATR) 0.36 0.49
MACD -0.10 0.13
Stochastic Oscillator 5.00 60.87

Price Performance

Historical Comparison
AURA
VNDA

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: